Determination of volatile phenols in red wines by dispersive liquid-liquid microextraction and gas chromatography-mass spectrometry detection.

by
A new method was developed for analysing 4-ethylguaiacol and 4-ethylphenol in the aroma of red wines using dispersive liquid-liquid microextraction (DLLME) coupled with gas chromatography-mass spectrometry detection (GC-MS).
Parameters such as extraction solvent, sample volume and disperser solvent were studied and optimised to obtain the best extraction results with the minimum interference from other substances, thus giving clean chromatograms. The response linearity was studied in the usual concentration ranges of analytes in wines (50-1500 microg/L). Repeatability and reproducibility of this method were lower than 5% for both volatile phenols.
Limits of detection and limits of quantification were also determined, and the values found were 28 and 95 microg/L for 4-ethylguaiacol and 44 and 147 microg/L for 4-ethylphenol, respectively.
This new method has been used for the determination of the volatile phenols concentration in different samples of Tannat wine affected by Brettanomyces contamination.

High-performance liquid chromatography method development and validation for simultaneous determination of five model compounds, antipyrine, metoprolol, ketoprofen, furosemide and phenol red, as a tool for the standardization of rat in situ intestinal permeability studies using timed wavelength detection.

A simple, precise, accurate and rugged reversed-phase high-performance liquid chromatography (HPLC) method has been developed and validated for the simultaneous determination of five permeability model compounds, viz. antipyrine, metoprolol, ketoprofen, furosemide and phenol red.
The method was intended to standardize rat in situ single-pass intestinal perfusion studies to assess the intestinal permeability of drugs in the market as well as new chemical entities. Optimum resolution was achieved by gradient elution on a Symmetry Shield C-18 analytical column with the mobile phase consisting of a mixture of aqueous potassium dihydrogen orthophosphate (pH 5.5; 0.01 m) and methanol at a flow rate of 1.5 mL/min.
The retention times of antipyrine, metoprolol, ketoprofen, phenol red and furosemide were about 9, 12, 13, 16 and 17 min, respectively. Data acquisition was carried out using a photo diode array detector in the wavelength range 210-600 nm. Extraction of chromatograms was carried out by timed wavelength.
Data obtained in all studies indicated that the method was suitable for the intended purpose. The validated method was found to be linear and precise in the working range. Suitability of storage under various conditions and freeze/thaw impact at cold temperature were established to ensure complete sample recovery without any stability issues. Recovery very close to the spiked amounts indicated that the method was highly accurate and suitable for use on routine basis.

A simple and rapid high-performance liquid chromatography method for determining furosemide, hydrochlorothiazide, and phenol red: applicability to intestinal permeability studies.

A simple reversed-phase high-performance liquid chromatography (HPLC) method with ultraviolet detection at 280 nm was developed for simultaneous quantitation of furosemide and hydrochlorothiazide along with phenol red as a nonabsorbable marker for in situ permeability studies in anaesthetized rats.
A jejunal segment of approximately 10 cm was isolated and cannulated in both ends for inlet and outlet solution. The perfusate was collected every 10 min, and samples were analyzed using the developed method.
The mobile phase was acetonitrile-water-triethylamine-glacial acetic acid (41.5 + 57.4 + 0.1 + 0.9, adjusted to pH 5.6) at a flow rate of 1 mL/min; the run time was 9 min. The calibration graphs were linear for all 3 compounds (r>> 0.999) across the concentration range of 7.93-125 microg/mL for phenol red and 6.25-100 microg/mL for hydrochlorothiazide and furosemide.
The limits of quantitation were 7.2, 8.9, and 6.8 microg/mL for furosemide, hydrochlorothiazide, and phenol red, respectively. The coefficients of variation for intraassay and interassay precision were less than or equal to 7.6%, and the accuracy was between 93.2-103.4%. Using the single pass intestinal perfusion technique and the suggested HPLC method for sample analysis, mean values of 0.25 x 10(-4) (+/-0.16) cm/s and 0.22 x 10(-4) (+/-0.13) cm/s were obtained for furosemide and hydrochlorothiazide, respectively.

Construction of a colorimetric sensor array based on the coupling reaction to identify phenols

Phenols are harmful to the human body and the environment. Since there are a variety of phenols in actual samples, this requires a sensor which possesses the ability to simultaneously distinguish them. Herein, we report a colorimetric sensor array, which uses two nanozymes (Fe-N-C nanozymes and Cu-N-C nanozymes) as electronic tongues for fingerprint identification of six phenols (2,4,6-trichlorophenol (2,4,6-Tri), 4-nitrophenol (P-np), phenol (Phe), 3-chlorophenol (3-CP), 4-chlorophenol (4-CP), and o-nitrophenol (O-np)) in the environment.
Nanozymes catalyzed the reaction of hydrogen peroxide, different phenols and 4-aminoantipyrine (4-AAP) to produce different color variations. These signal changes as fingerprints encouraged us to develop a pattern recognition method for the identification of phenols by linear discriminant analysis (LDA). The six phenols at 50 nM have their own response patterns, respectively. Surprisingly, this sensor array had distinguished the six phenols in actual samples successfully.

Ultrafast Proton-Transfer Reaction in Phenol-(Ammonia) n Clusters: An Ab Initio Molecular Dynamics Investigation

The ability of phenol to transfer a proton to surrounding ammonia molecules in a phenol-(ammonia)n cluster depends on the relative orientation of ammonia molecules, and a critical field of about 285 MV cm-1 is essential along the O-H bond for the proton-transfer process. Ab initio MD simulations reveal that the proton-transfer process from phenol to ammonia cluster is spontaneous when the cluster has at least eight ammonia molecules, and the proton-transfer event is almost instantaneous (about 20-120 fs).
These simulations also reveal that the rate-determining step for the proton-transfer process is the reorganization of the solvent around the OH group.
During the solvent reorganization process, the fluctuations in the solvent occur until a particular set of configurations projects the field in excess of the critical electric field along the O-H bond which drives the proton-transfer process. Further, the proton-transfer process follows a curvilinear path which includes the O-H bond elongation and out-of-plane movement of the proton and can be referred to as a “bend-to-break” process.

Inhibition studies of bacterial α-carbonic anhydrases with phenols

The α-class carbonic anhydrases (CAs, EC 4.2.1.1) from the bacterial pathogens Neisseria gonorrhoeae (NgCAα) and Vibrio cholerae (VchCAα) were investigated for their inhibition by a panel of phenols and phenolic acids. Mono-, di- and tri-substituted phenols incorporating additional hydroxyl/hydroxymethyl, amino, acetamido, carboxyl, halogeno and carboxyethenyl moieties were included in the study.

Phenol red

 from Bio Basic
PB0420 | 25g: 85.06 EUR

Phenol Red

 from Glentham Life Sciences
GT9844-100G | 100 g: 132.00 EUR

Phenol Red

 from Glentham Life Sciences
GT9844-250G | 250 g: 217.20 EUR

Phenol Red

 from Glentham Life Sciences
GT9844-25G | 25 g: 74.40 EUR

Phenol Red

 from Glentham Life Sciences
GT9844-5G | 5 g: 55.20 EUR

Phenol Red

 from Glentham Life Sciences
GT9844-100 | 100: 79.10 EUR

Phenol Red

 from Glentham Life Sciences
GT9844-25 | 25: 31.70 EUR

Phenol Red

 from Glentham Life Sciences
GT9844-250 | 250: 150.40 EUR

Phenol Red

 from Glentham Life Sciences
GT9844-5 | 5: 15.90 EUR

Phenol Red Solution

 from GenDepot
CA013-010 | 100ml: 82.80 EUR

PHENOL RED BROTH BASE

 from Alphabiosciences
P16-104-10kg | 10 kg: 1078.80 EUR

PHENOL RED BROTH BASE

 from Alphabiosciences
P16-104-2kg | 2kg: 280.80 EUR

PHENOL RED BROTH BASE

 from Alphabiosciences
P16-104-500g | 500 g: 120.00 EUR

Ceraplex , No Phenol red

 from GenDepot
C3320-050 | 500ml: Ask for price

Phenol red, sodium salt

 from Bio Basic
PD0424 | 25g: 76.70 EUR

Phenol Red sodium salt

 from Glentham Life Sciences
GT6682-100G | 100 g: 170.40 EUR

Phenol Red sodium salt

 from Glentham Life Sciences
GT6682-25G | 25 g: 84.00 EUR

Phenol Red sodium salt

 from Glentham Life Sciences
GT6682-5G | 5 g: 52.80 EUR

Phenol Red (sodium salt)

 from MedChemExpress
HY-D0169A | 500mg: 129.60 EUR

Phenol Red sodium salt

 from Glentham Life Sciences
GT6682-100 | 100: 110.70 EUR

Phenol Red sodium salt

 from Glentham Life Sciences
GT6682-25 | 25: 39.40 EUR

Phenol Red sodium salt

 from Glentham Life Sciences
GT6682-5 | 5: 15.70 EUR
The best NgCAα inhibitrs were phenol, 3-aminophenol, 4-hydroxy-benzylalcohol, 3-amino-4-chlorophenol and paracetamol, with KI values of 0.6-1.7 µM. The most effective VchCAα inhibitrs were phenol, 3-amino-4-chlorophenol and 4-hydroxy-benzyl-alcohol, with KI values of 0.7-1.2 µM. Small changes in the phenol scaffold led to drastic effects on the bacterial CA inhibitory activity. This class of underinvestigated bacterial CA inhibitors may thus lead to effective compounds for fighting drug resistant bacteria.

Isolation of exosome from the culture medium of Nasopharyngeal cancer (NPC) C666-1 cells using inertial based Microfluidic channel

by
Isolation of exosome from culture medium in an effective way is desired for a less time consuming, cost saving technology in running the diagnostic test on cancer. In this study, we aim to develop an inertial microfluidic channel to separate the nano-size exosome from C666-1 cell culture medium as a selective sample. Simulation was carried out to obtain the optimum flow rate for determining the dimension of the channels for the exosome separation from the medium.
The optimal dimension was then brought forward for the actual microfluidic channel fabrication, which consisted of the stages of mask printing, SU8 mould fabrication and ended with PDMS microchannel curing process. The prototype was then used to verify the optimum flow rate with polystyrene particles for its capabilities in the actual task on particle separation as a control outcome. Next, the microchip was employed to separate the selected samples, exosome from the culture medium and compared the outcome from the conventional exosome extraction kit to study the level of effectiveness of the prototype.
The exosome outcome from both the prototype and extraction kits were characterized through zetasizer, western blot and Transmission electron microscopy (TEM). The microfluidic chip designed in this study obtained a successful separation of exosomes from the culture medium. Besides, the extra benefit from these microfluidic channels in particle separation brought an evenly distributed exosome upon collection https://joplink.net/exosome-isolation-kits/ while the exosomes separated through the extraction kit was found clustered together. Therefore, this work has shown the microfluidic channel is suitable for continuous separation of exosomes from the culture medium for a clinical study in the future.

Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer

Background: Breast cancer is the most common cancer, and the leading cause of cancer-related deaths, among females world-wide. Recent research suggests that extracellular vesicles (EVs) play a major role in the development of breast cancer metastasis. Axillary lymph node dissection (ALND) is a procedure in patients with known lymph node metastases, and after surgery large amounts of serous fluid are produced from the axilla. The overall aim was to isolate and characterize EVs from axillary serous fluid, and more specifically to determine if potential breast cancer biomarkers could be identified.
Methods: Lymphatic drain fluid was collected from 7 patients with breast cancer the day after ALND. EVs were isolated using size exclusion chromatography, quantified and detected by nanoparticle tracking analysis, electron microscopy, nano flow cytometry and western blot. The expression of 37 EV surface proteins was evaluated by flow cytometry using the MACSPlex Exosome kit.
Results: Lymphatic drainage exudate retrieved after surgery from all 7 patients contained EVs. The isolated EVs were positive for the typical EV markers CD9, CD63, CD81 and Flotillin-1 while albumin was absent, indicating low contamination from blood proteins. In total, 24 different EV surface proteins were detected.
Eleven of those proteins were detected in all patients, including the common EV markers CD9, CD63 and CD81, cancer-related markers CD24, CD29, CD44 and CD146, platelet markers CD41b, CD42a and CD62p as well as HLA-DR/DP/DQ. Furthermore, CD29 and CD146 were enriched in Her2+ patients compared to patients with Her2- tumors.
Conclusions: Lymphatic drainage exudate retrieved from breast cancer patients after surgery contains EVs that can be isolated using SEC isolation. The EVs have several cancer-related markers including CD24, CD29, CD44 and CD146, proteins of potential interest as biomarkers as well as to increase the understanding of the mechanisms of cancer biology.

Understanding the Role and Clinical Applications of Exosomes in Gynecologic Malignancies: A Review of the Current Literature

Background: Gynecologic malignancies are those which arise in the female reproductive organs of the ovaries, cervix, and uterus. They carry a great deal of morbidity and mortality for patients, largely due to challenges in diagnosis and treatment of these cancers. Although advances in technology and understanding of these diseases have greatly improved diagnosis, treatment, and ultimately survival for patients with gynecologic malignancies over the last few decades, there is still room for improvements in diagnosis and treatment, for which exosomes may be the key. This paper reviews the current knowledge regarding gynecologic tumor derived-exosomal genetic material and proteins, their role in cancer progression, and their potential for advancing the clinical care of patients with gynecologic cancers through novel diagnostics and therapeutics.
Literature review: Ovarian tumor derived exosome specific proteins are reviewed in detail, discussing their role in ovarian cancer metastasis. The key microRNAs in cervical cancer and their implications in future clinical use are discussed. Additionally, uterine cancer-associated fibroblast (CAF)-derived exosomes which may promote endometrial cancer cell migration and invasion through a specific miR-148b are reviewed. The various laboratory techniques and commercial kits for the isolation of exosomes to allow for their clinical utilization are described as well.
Conclusion: Exosomes may be the key to solving many unanswered questions, and closing the gaps so as to improve the outcomes of patients with gynecologic cancers around the world. The potential utilization of the current knowledge of exosomes, as they relate to gynecologic cancers, to advance the field and bridge the gaps in diagnostics and therapeutics highlight the promising future of exosomes in gynecologic malignancies.

Pathogenic Mechanisms of Preeclampsia with Severe Features Implied by the Plasma Exosomal miRNA Profile

Preeclampsia is a complication of pregnancy characterised by high blood pressure and organ damage after 20 gestational weeks. It is associated with high maternal and fetal morbidity and mortality; however, at present, there is no effective prevention or treatment for this condition. Previous studies have revealed that plasma exosomal miRNAs from pregnant women with preeclampsia could serve as biomarkers of pathogenic factors. However, the roles of plasma exosomal miRNAs in preeclampsia with severe features (sPE), which is associated with poorer pregnancy outcomes, remain unknown.
Thus, the aims of this study were to characterise plasma exosomal miRNAs in sPE and explore the related pathogenic mechanisms using bioinformatic analysis. Plasma exosomes were isolated using a mirVana RNA isolation kit.
The exosomal miRNAs were detected using high-throughput sequencing and the miRNAs related to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and gene ontology (GO) terms were analysed using the clusterProfiler package of R. Fifteen miRNAs exhibited increased expression and fourteen miRNAs exhibited reduced expression in plasma exosomes from women with sPE as compared to normal pregnant women.
Further, gene set enrichment analysis revealed that the differentially expressed plasma exosomal miRNAs were related to the stress response and cell junction regulation, among others. In summary, this study is the first to identify the differentially expressed plasma exosomal miRNAs in sPE. These findings highlight promising pathogenesis mechanisms underlying preeclampsia.

Exosome Isolation kit (for cell culture media)
- Ask for price

Exosome Isolation kit (for cell culture media)
- Ask for price

Exosome Isolation kit (for cell culture media)
- Ask for price

Exosome Isolation kit (for stem cell culture media)
- Ask for price

Exosome Isolation kit (for stem cell culture media)
- Ask for price

VEX Exosome Isolation Reagent (from cell culture media)
50 ml 706.8 EUR

Reagent for Total Exosome Isolation (Culture Media Supplement)
50 ml 2485.2 EUR

ExoQuick Exosome Isolation and RNA Purification kit (for Tissue Culture Media)
10 preps 493 EUR

Exosome Isolation kit (for urine)
- Ask for price

Exosome Isolation kit (for urine)
- Ask for price

GenMark ePlex NATtrol

by

In March, GenMark received EUA for its ePlex SARS-CoV-2 Test. Respiratory Pathogen Panel. Multiplex molecular diagnostic solutions provider GenMark Diagnostics has secured CE mark approval for its ePlex respiratory pathogen panel 2 (RP2). The ePlex RP has received FDA clearance for nasopharyngeal swab (NPS) specimens collected in viral transport media. COVID-19. ;

The RP2 Panel provides results in less than two hours for more than 20 viruses and bacteria that cause common respiratory infections with similar symptoms, including COVID-19, flu, bronchitis, and the common cold. Clinical implications of rapid eplex® respiratory pathogen panel testing compared to laboratory-developed real-time PCR Anneloes L. van Rijn, Roel H.T. Due to the batch-wise testing, laboratory-developed real-time polymerase chain reaction (PCR) assays (LDT) often result in a time to result of one day.

10/01/2019: Under Article Text added the third bullet point verbiage “For dates of service on or after 10/1/2019, laboratories billing for services using GenMark” ePlex Respiratory Pathogen (RP) Panel should report 0115U. The ePlex RP2 Control M451 is composed of synthetic DNA and RNA specifically designed for and intended to be used solely with the ePlex RP2 Panel on the ePlex System. In March, GenMark received EUA for its ePlex SARS-CoV-2 Test. Read More.

The ePlex respiratory pathogen panel (RP panel) is a novel molecular biology-based assay, developed by GenMark Diagnostics, Inc. (Carlsbad, CA), to be performed within a single cartridge for the diagnosis of 25 respiratory pathogens (viral and bacterial). in Top News. GenMarkâs ePLex-BCID Gram-Positive panel detects 20 bacterial targets, and the Fungal Pathogen panel detects 13 yeast pathogens in one and a half hours. AB Molecular Ltd. Butyl Road, Botolph Claydon, Respiratory Pathogen Panel. AB Molecular is the exclusive distributor in the UK for GenMark Dx and has been established to promote their innovative ePlex technology.

The ePlex RP2 Panel is designed for use with the companyâs ePlex system, which has been cleared by the FDA for use with the ePlex Respiratory Pathogen (RP) Panel and Blood Culture Identification (BCID) Panels (Gram-positive, Gram-negative and Fungal pathogens). The QIAstat-Dx® RP assay detected 312 of the 338 respiratory targets (92%) that were detected by the ePlex® RPP assay. This assay does NOT detect SARS CoV-2 (novel coronavirus) or MERS. Multiplex molecular panels provide high sensitivity (few false negatives) and specificity (few false positives) for multiple pathogens in ⦠GenMarkâs ePlex Respiratory Pathogen Panel 2 (RP2) achieves CE mark.

The company said RP2 drove the majority of the placements and revenues in Q3. Respiratory Panel 2 (RP2)] 0115U Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected [USE FOR GenMark ePlex Respiratory Pathogen (RP) Panel] SARS-CoV-2 (2 assays) Seasonal coronavirus.

We are very pleased to announce the 510(k) clearance of ePlex and the Respiratory Pathogen Panel. The new RP2 panel includes SARS-CoV-2, the pathogen that causes COVID-19. If the tube system is used, ensure specimens are in leak-proof containers that are securely closed and double bagged. ORIGINAL ARTICLE Clinical implications of rapid ePlex® Respiratory Pathogen Panel testing compared to laboratory-developed real-time PCR Anneloes L. van Rijn1 & Roel H. T. Nijhuis1 & Vincent Bekker 2 & Geert H.

Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report.

by
Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report.

This report has been ready by the European Academy of Allergy and Clinical Immunology Task Force on Allergic Rhinitis (AR) comorbidities. The goal of this multidisciplinary European consensus doc is to spotlight the function of multimorbidities in the definition, classification, mechanisms, suggestions for prognosis and remedy of AR, and to outline the wants in this uncared for space by a literature overview.

AR is a systemic allergic illness and is mostly related to quite a few multi-morbid problems, together with bronchial asthma, eczema, meals allergic reactions, eosinophilic oesophagitis (EoE), conjunctivitis, power center ear effusions, rhinosinusitis, adenoid hypertrophy, olfaction problems, obstructive sleep apnea, disordered sleep and consequent behavioural and instructional results.

This report supplies up-to-date usable data to: (1) enhance the data and expertise of allergists, in order to in the end enhance the general high quality of affected person care; (2) to extend curiosity in this space; and (3) to current a singular contribution to the sphere of higher inflammatory illness.

Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report.
Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report.

A piece group report on ultrafine particles (American Academy of Allergy, Asthma & Immunology): Why ambient ultrafine and engineered nanoparticles ought to obtain particular consideration for doable hostile well being outcomes in human topics.

Ultrafine particles (UFPs) are airborne particulates of lower than 100 nm in aerodynamic diameter. Examples of UFPs are diesel exhaust particles, merchandise of cooking, heating, and wooden burning in indoor environments, and, extra not too long ago, merchandise generated by the use of nanotechnology. Studies have proven that ambient UFPs have detrimental results on each the cardiovascular and respiratory techniques, together with the next incidence of atherosclerosis and exacerbation fee of bronchial asthma.

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC942185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF594 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC942598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF594 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC942598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF594 conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC802185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF680 conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC802185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF680 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC802598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF680 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC802598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF680 conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC702185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF770 conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC702185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF770 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC702598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF770 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC702598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF770 conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC882185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF488A conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC882185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF488A conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC882598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF488A conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC882598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF488A conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC812185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF680R conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC812185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF680R conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC812598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF680R conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC812598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF680R conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC052185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF405M conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC052185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF405M conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC042185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF405S conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC042185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF405S conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC402185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF640R conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC402185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF640R conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC402598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF640R conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC402598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF640R conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC052598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF405M conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC052598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF405M conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC042598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF405S conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC042598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF405S conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNCAP2185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNCAP2185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNCAP2598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNCAP2598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNCA2185-250 250uL
EUR 472.8
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), APC conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNCA2598-250 250uL
EUR 472.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), APC conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNCP2185-250 250uL
EUR 472.8
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), PerCP conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNCP2598-250 250uL
EUR 472.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), PerCP conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNCR2185-250 250uL
EUR 472.8
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), RPE conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNCR2598-250 250uL
EUR 472.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), RPE conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNCH2185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNCH2185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNCH2598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNCH2598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNCB2185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), Biotin conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNCB2185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), Biotin conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNCB2598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), Biotin conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNCB2598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), Biotin conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNUB2185-100 100uL
EUR 316.8
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), Concentration: 0.2mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNUB2185-50 50uL
EUR 486
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), 1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNUB2185-500 500uL
EUR 615.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), Concentration: 0.2mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNUB2598-100 100uL
EUR 316.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), Concentration: 0.2mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNUB2598-50 50uL
EUR 486
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), 1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNUB2598-500 500uL
EUR 615.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), Concentration: 0.2mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC472185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF647 conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC472185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF647 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC472598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF647 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC472598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF647 conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC552185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF555 conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC552185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF555 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC552598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF555 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC552598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF555 conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC612185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF660R conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC612185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF660R conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC612598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF660R conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC612598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF660R conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC432185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF543 conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC432185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF543 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC432598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF543 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC432598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF543 conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC682185-100 100uL
EUR 279.6
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF568 conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185) Antibody
BNC682185-500 500uL
EUR 654
Description: Primary antibody against Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) (PODXL/2185), CF568 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC682598-100 100uL
EUR 279.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF568 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R) Antibody
BNC682598-500 500uL
EUR 654
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/2598R), CF568 conjugate, Concentration: 0.1mg/mL

anti-CD34 Hematopoietic precursor cells
513-A-01mg 0,1 mg
EUR 321
Description: anti-CD34 Hematopoietic precursor cells

anti-CD34 Hematopoietic precursor cells
513-A-1000ug 1000 ug
EUR 1539
Description: anti-CD34 Hematopoietic precursor cells

anti-CD34 Hematopoietic precursor cells
513-A-100ugvial 100 ug/vial
EUR 150
Description: anti-CD34 Hematopoietic precursor cells

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC941806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF594 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC941806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF594 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC801806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF680 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC801806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF680 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC701806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF770 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC701806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF770 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC881806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF488A conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC881806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF488A conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC811806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF680R conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC811806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF680R conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC051806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF405M conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC051806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF405M conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC041806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF405S conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC041806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF405S conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC401806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF640R conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC401806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF640R conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNCAP1806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNCAP1806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNCA1806-250 250uL
EUR 459.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),APC conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNCP1806-250 250uL
EUR 459.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),PerCP conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNCR1806-250 250uL
EUR 459.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),RPE conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNCH1806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNCH1806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNCB1806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),Biotin conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNCB1806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),Biotin conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNUB1806-100 100uL
EUR 250.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R), Concentration: 0.2mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNUB1806-500 500uL
EUR 549.6
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R), Concentration: 0.2mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNUM1806-50 50uL
EUR 474
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R), 1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC471806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF647 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC471806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF647 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC611806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF660R conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC611806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF660R conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC431806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF543 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC431806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF543 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC551806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF555 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC551806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF555 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC681806-100 100uL
EUR 238.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF568 conjugate, Concentration: 0.1mg/mL

CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R) Antibody
BNC681806-500 500uL
EUR 652.8
Description: Primary antibody against CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R),CF568 conjugate, Concentration: 0.1mg/mL

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker); Clone 3D3 (Concentrate)
RA0264-C.1 0.1 ml
EUR 150

Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker); Clone 3D3 (Concentrate)
RA0264-C.5 0.5 ml
EUR 360

CD34 (Hematopoietic Stem Cell & Endothelial Marker); Clone QBEnd/10 (Concentrate)
RA0052-C.1 0.1 ml
EUR 150

CD34 (Hematopoietic Stem Cell & Endothelial Marker); Clone QBEnd/10 (Concentrate)
RA0052-C.5 0.5 ml
EUR 360

CD34 (Hematopoietic Stem Cell & Endothelial Marker); Clone HPCA1/763 (Concentrate)
RA0053-C.1 0.1 ml
EUR 150

CD34 (Hematopoietic Stem Cell & Endothelial Marker); Clone HPCA1/763 (Concentrate)
RA0053-C.5 0.5 ml
EUR 360

Anti-Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) Monoclonal Antibody
M03359 100ug/vial
EUR 476.4
Description: Mouse Monoclonal Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) Antibody. Validated in Flow Cytometry, IP and tested in Human, Rabbit, Rat.

Rat Bone Marrow PrimaCell: Hematopoietic Cells
2-82590 1 Kit Ask for price

Mouse Bone Marrow PrimaCell: Hematopoietic Cells
2-82094 1 Kit Ask for price

Human Bone Marrow PrimaCell: Hematopoietic Cells
2-96116 1 Kit Ask for price

Monoclonal Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) Antibody, Clone: 3D3
AMM01202G 7 ml
EUR 580.8
Description: A Monoclonal antibody against Human Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker). The antibodies are raised in Mouse and are from clone 3D3. This antibody is applicable in WB, IHC and IF, FC, IP

Monoclonal Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) Antibody, Clone: 2A4
AMM01205G 7 ml
EUR 580.8
Description: A Monoclonal antibody against Human Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker). The antibodies are raised in Mouse and are from clone 2A4. This antibody is applicable in IHC, IF, FC

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody, Clone: SPM123
AMM01547G 7 ml
EUR 580.8
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker). The antibodies are raised in Mouse and are from clone SPM123. This antibody is applicable in IHC, IF, FC

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody, Clone: SPM610
AMM01557G 7 ml
EUR 580.8
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker). The antibodies are raised in Mouse and are from clone SPM610. This antibody is applicable in WB, IHC and IF, FC

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody, Clone: QBEnd/10
AMM01546G 7 ml
EUR 580.8
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker). The antibodies are raised in Mouse and are from clone QBEnd/10. This antibody is applicable in IHC, IF, FC

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody, Clone: HPCA1/763
AMM01548G 7 ml
EUR 580.8
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker). The antibodies are raised in Mouse and are from clone HPCA1/763. This antibody is applicable in IHC, IF, FC

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody, Clone: HPCA1/1171
AMM01554G 7 ml
EUR 580.8
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker). The antibodies are raised in Mouse and are from clone HPCA1/1171. This antibody is applicable in WB, IHC and IF, FC

CD34 (Hematopoietic Stem Cell & Endothelial Marker); Clone QBEnd/10 & HPCA1/763 (Concentrate)
RA0054-C.1 0.1 ml
EUR 150

CD34 (Hematopoietic Stem Cell & Endothelial Marker); Clone QBEnd/10 & HPCA1/763 (Concentrate)
RA0054-C.5 0.5 ml
EUR 360

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody, Clone: QBEnd/10 + HPCA1/763
AMM01551G 7 ml
EUR 580.8
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker). The antibodies are raised in Mouse and are from clone QBEnd/10 + HPCA1/763. This antibody is applicable in IHC, IF, FC

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody - Without BSA, Clone: SPM123
AMM00477G 0.1mg
EUR 580.8
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker) - Without BSA. The antibodies are raised in Mouse and are from clone SPM123. This antibody is applicable in IHC-P, IF, FC

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody - Without BSA, Clone: HPCA1/763
AMM01550G 0.1mg
EUR 580.8
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker) - Without BSA. The antibodies are raised in Mouse and are from clone HPCA1/763. This antibody is applicable in IHC, IF, FC

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody - Without BSA, Clone: QBEnd/10
AMM00475G 0.1mg
EUR 580.8
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker) - Without BSA. The antibodies are raised in Mouse and are from clone QBEnd/10. This antibody is applicable in IHC-P, IF, FC

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody - With BSA and Azide, Clone: SPM610
AMM01558G 0.05mg
EUR 475.2
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone SPM610. This antibody is applicable in WB, IHC and IF, FC

Monoclonal Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) Antibody - With BSA and Azide, Clone: 3D3
AMM00046G 0.05mg
EUR 475.2
Description: A Monoclonal antibody against Human Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone 3D3. This antibody is applicable in WB and IHC, FC, IP, E

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody - Conjugated to PE , Clone: ICO-115
AMM00132G 0.05mg
EUR 475.2
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker) - Conjugated to PE . The antibodies are raised in Mouse and are from clone ICO-115. This antibody is applicable in FC

Monoclonal Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) Antibody - Without BSA and Azide, Clone: 3D3
AMM00369G 0.1mg
EUR 580.8
Description: A Monoclonal antibody against Human Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone 3D3. This antibody is applicable in WB and IHC-P, IF, FC, IP

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody - With BSA and Azide, Clone: SPM123
AMM00476G 0.05mg
EUR 475.2
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone SPM123. This antibody is applicable in IHC-P, IF, FC

Monoclonal Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) Antibody - With BSA and Azide, Clone: 4F10
AMM01203G 0.05mg
EUR 475.2
Description: A Monoclonal antibody against Human Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone 4F10. This antibody is applicable in IHC, IF, FC

Monoclonal Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) Antibody - With BSA and Azide, Clone: 2A4
AMM01206G 0.05mg
EUR 475.2
Description: A Monoclonal antibody against Human Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone 2A4. This antibody is applicable in IHC, IF, FC

Monoclonal Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) Antibody - Without BSA and Azide, Clone: 2A4
AMM01207G 0.1mg
EUR 580.8
Description: A Monoclonal antibody against Human Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone 2A4. This antibody is applicable in IHC, IF, FC

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody - With BSA and Azide, Clone: HPCA1/763
AMM01549G 0.05mg
EUR 475.2
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone HPCA1/763. This antibody is applicable in IHC, IF, FC

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody - Without BSA, Clone: QBEnd/10 + HPCA1/763
AMM01553G 0.1mg
EUR 580.8
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker) - Without BSA. The antibodies are raised in Mouse and are from clone QBEnd/10 + HPCA1/763. This antibody is applicable in IHC, IF, FC

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody - With BSA and Azide, Clone: HPCA1/1171
AMM01555G 0.05mg
EUR 475.2
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone HPCA1/1171. This antibody is applicable in WB, IHC and IF, FC

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody - With BSA and Azide, Clone: ICO-115
AMM00133G 0.05mg
EUR 475.2
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone ICO-115. This antibody is applicable in WB and IHC, FC, IP

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody - With BSA and Azide, Clone: QBEnd/10
AMM00182G 0.05mg
EUR 475.2
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone QBEnd/10. This antibody is applicable in WB and IHC, FC, IP

Monoclonal CD34 (Hematopoietic Stem Cell & Endothelial Marker) Antibody - Without BSA and Azide, Clone: SPM610
AMM01559G 0.1mg
EUR 580.8
Description: A Monoclonal antibody against Human CD34 (Hematopoietic Stem Cell & Endothelial Marker) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone SPM610. This antibody is applicable in WB, IHC and IF, FC

Monoclonal Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) Antibody - Without BSA and Azide, Clone: 4F10
AMM01204G 0.1mg
EUR 580.8
Description: A Monoclonal antibody against Human Podocalyxin (PODXL) (Hematopoietic Stem Cell Marker) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone 4F10. This antibody is applicable in IHC, IF, FC

Rat Bone Marrow PrimaCell: Normal Hematopoietic Cells Growth Medium
9-25090 5 x 100 ml Ask for price

UFPs have been discovered to change in vitro and in vivo responses of the immune system to allergens and may also play a task in allergen sensitization. The inflammatory properties of UFPs may be mediated by a quantity of totally different mechanisms, together with the power to provide reactive oxygen species, resulting in the era of proinflammatory cytokines and airway irritation.

In addition, as a result of of their small measurement, UFPs even have distinctive distribution traits in the respiratory tree and circulation and would possibly be capable of alter mobile perform in ways in which circumvent regular signaling pathways.

Additionally, UFPs can penetrate intracellularly and probably trigger DNA injury. The current advances in nanotechnology, though opening up new alternatives for the development of expertise and medication, may additionally result in unexpected hostile well being results in uncovered human topics.

Further analysis is required to make clear the protection of nanoscale particles, in addition to the elucidation of the doable helpful use of these particulates to deal with illness.

AllergoOncology: Microbiota in allergy and cancer-A European Academy for Allergy and Clinical Immunology position paper.

by
AllergoOncology: Microbiota in allergy and cancer-A European Academy for Allergy and Clinical Immunology position paper.
The microbiota can play necessary roles in the event of human immunity and the institution of immune homeostasis. Lifestyle elements together with food regimen, hygiene, and publicity to viruses or micro organism, and medical interventions with antibiotics or anti-ulcer medicines, regulate phylogenetic variability and the standard of cross speak between innate and adaptive immune cells through mucosal and pores and skin epithelia.
More just lately, microbiota and their composition have been linked to protecting results for well being. Imbalance, nonetheless, has been linked to immune-related ailments comparable to allergy and most cancers, characterised by impaired, or exaggerated immune tolerance, respectively.
In this AllergoOncology position paper, we give attention to the growing proof defining the microbiota composition as a key determinant of immunity and immune tolerance, linked to the chance for the event of allergic and malignant ailments. We focus on novel insights into the function of microbiota in illness and affected person responses to remedies in most cancers and in allergy.
These might spotlight alternatives to enhance affected person outcomes with medical interventions supported by way of a restored microbiome.
AllergoOncology: Microbiota in allergy and cancer-A European Academy for Allergy and Clinical Immunology position paper.
AllergoOncology: Microbiota in allergy and cancer-A European Academy for Allergy and Clinical Immunology position paper.

Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force.

by
Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force.

A Task Force was commissioned collectively by the European Academy of Allergy and Clinical Immunology (EAACI) and the Respiratory Effectiveness Group (REG) to develop a high quality evaluation device for real-life observational analysis to establish high-quality real-life bronchial asthma research that might be thought-about inside future guideline growth.The ensuing REal Life EVidence AssessmeNt Tool (RELEVANT) was achieved by way of an intensive evaluation of present initiatives in this space.

The first model was piloted amongst 9 raters throughout 6 articles; the revised, interim, model underwent in depth testing by 22 reviewers from the EAACI membership and REG collaborator group, resulting in additional revisions and device finalisation. RELEVANT was validated by way of an evaluation of real-life effectiveness research recognized by way of systematic evaluate of Medline and Embase databases and regarding subjects for which real-life research might provide priceless proof complementary to that from randomised managed trials.

The subjects have been chosen by way of a vote amongst Task Force members and associated to the affect of adherence, smoking, inhaler machine and particle measurement on bronchial asthma remedy effectiveness.Although highlighting a basic lack of high-quality real-life effectiveness observational analysis on these clinically vital subjects, the evaluation offered insights into how recognized observational research may inform bronchial asthma pointers builders and clinicians.

Overall, RELEVANT appeared dependable and straightforward to make use of by professional reviewers.Using such high quality appraisal instruments is obligatory to evaluate whether or not particular observational real-life effectiveness research can be utilized to tell guideline growth and/or decision-making in medical observe.

Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force.
Quality standards in respiratory real-life effectiveness analysis: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force.

New European Academy of Allergy and Clinical Immunology definition on pollen season mirrors symptom load for grass and birch pollen-induced allergic rhinitis.

BACKGROUND
The use of allergen immunotherapy (AIT) for allergic rhinitis and its medical efficacy in medical trials will depend on the efficient dedication of pollen allergen publicity time durations. We consider pollen information from Germany to look at the new definitions on pollen season and peak pollen interval begin and finish as proposed by the European Academy of Allergy and Clinical Immunology (EAACI) in a just lately printed Position Paper. The goal was to reveal the potential of these definitions to reflect symptom hundreds for grass and birch pollen-induced allergic rhinitis primarily based on real-life information.

FBXW7 antibody
70R-6541 50 ug
EUR 560.4
Description: Rabbit polyclonal FBXW7 antibody raised against the C terminal of FBXW7

FBXW7 Antibody
36334-100ul 100ul
EUR 302.4

FBXW7 Antibody
DF12400 200ul
EUR 420

FBXW7 Antibody
1-CSB-PA251991
  • EUR 380.40
  • EUR 292.80
  • 100ul
  • 50ul
Description: A polyclonal antibody against FBXW7. Recognizes FBXW7 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:10000, IHC:1:100-1:300

FBXW7 Antibody
1-CSB-PA822163LA01HU
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against FBXW7. Recognizes FBXW7 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200

FBXW7 Antibody
1-CSB-PA623964
  • EUR 380.40
  • EUR 292.80
  • 100ul
  • 50ul
Description: A polyclonal antibody against FBXW7. Recognizes FBXW7 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200

FBXW7 Antibody
F53267-0.08ML 0.08 ml
EUR 140.25
Description: Substrate recognition component of an SCF (SKP1-CUL1-F- box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes and binds phosphorylated sites/phosphodegrons within target proteins and thereafter bring them to the SCF complex for ubiquitination. Identified substrates include cyclin-E, MYC, NOTCH1 released notch intracellular domain (NICD), and probably PSEN1. [UniProt]

FBXW7 Antibody
F53267-0.4ML 0.4 ml
EUR 322.15
Description: Substrate recognition component of an SCF (SKP1-CUL1-F- box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes and binds phosphorylated sites/phosphodegrons within target proteins and thereafter bring them to the SCF complex for ubiquitination. Identified substrates include cyclin-E, MYC, NOTCH1 released notch intracellular domain (NICD), and probably PSEN1. [UniProt]

FBXW7 Antibody
F53304-0.08ML 0.08 ml
EUR 140.25
Description: Substrate recognition component of an SCF (SKP1-CUL1-F- box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes and binds phosphorylated sites/phosphodegrons within target proteins and thereafter bring them to the SCF complex for ubiquitination. Identified substrates include cyclin-E, MYC, NOTCH1 released notch intracellular domain (NICD), and probably PSEN1. [UniProt]

FBXW7 Antibody
F53304-0.4ML 0.4 ml
EUR 322.15
Description: Substrate recognition component of an SCF (SKP1-CUL1-F- box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes and binds phosphorylated sites/phosphodegrons within target proteins and thereafter bring them to the SCF complex for ubiquitination. Identified substrates include cyclin-E, MYC, NOTCH1 released notch intracellular domain (NICD), and probably PSEN1. [UniProt]

FBXW7 Rabbit pAb
A5872-100ul 100 ul
EUR 369.6

FBXW7 Rabbit pAb
A5872-200ul 200 ul
EUR 550.8

FBXW7 Rabbit pAb
A5872-20ul 20 ul
EUR 219.6

FBXW7 Rabbit pAb
A5872-50ul 50 ul
EUR 267.6

anti- FBXW7 antibody
FNab03057 100µg
EUR 702
Description: Antibody raised against FBXW7

FBXW7 cloning plasmid
CSB-CL822163HU-10ug 10ug
EUR 846
Description: A cloning plasmid for the FBXW7 gene.

FBXW7 Blocking Peptide
33R-5108 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of FBXW7 antibody, catalog no. 70R-6541

FBXW7 Blocking Peptide
DF12400-BP 1mg
EUR 234

pECMV- 3*Flag- FBXW7
PVT10356 2 ug
EUR 361.2

FBXW7 ELISA KIT|Human
EF009598 96 Tests
EUR 826.8

Mouse FBXW7 shRNA Plasmid
20-abx974100
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

Human FBXW7 shRNA Plasmid
20-abx960632
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

FBXW7 Antibody, HRP conjugated
1-CSB-PA822163LB01HU
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against FBXW7. Recognizes FBXW7 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

FBXW7 Antibody, FITC conjugated
1-CSB-PA822163LC01HU
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against FBXW7. Recognizes FBXW7 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

FBXW7 Recombinant Protein (Mouse)
RP134159 100 ug Ask for price

FBXW7 Recombinant Protein (Mouse)
RP134162 100 ug Ask for price

FBXW7 Recombinant Protein (Mouse)
RP134165 100 ug Ask for price

FBXW7 Recombinant Protein (Human)
RP039052 100 ug Ask for price

FBXW7 Antibody, Biotin conjugated
1-CSB-PA822163LD01HU
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against FBXW7. Recognizes FBXW7 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

FBXW7 ORF Vector (Human) (pORF)
ORF013018 1.0 ug DNA
EUR 114

Fbxw7 ORF Vector (Mouse) (pORF)
ORF044721 1.0 ug DNA
EUR 607.2

Fbxw7 ORF Vector (Mouse) (pORF)
ORF044722 1.0 ug DNA
EUR 607.2

Fbxw7 ORF Vector (Mouse) (pORF)
ORF044723 1.0 ug DNA
EUR 607.2

Polyclonal Fbxw7 antibody - middle region
APR00709G 0.05mg
EUR 633.6
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Fbxw7 - middle region. This antibody is tested and proven to work in the following applications:

Fbxw7 sgRNA CRISPR Lentivector set (Mouse)
K4531701 3 x 1.0 ug
EUR 406.8

FBXW7 sgRNA CRISPR Lentivector set (Human)
K0767601 3 x 1.0 ug
EUR 406.8

Fbxw7 3'UTR GFP Stable Cell Line
TU156466 1.0 ml Ask for price

FBXW7 3'UTR GFP Stable Cell Line
TU057813 1.0 ml
EUR 1825.2

Polyclonal FBXW7 / FBW7 Antibody (N-Terminus)
APR02668G 0.05mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human FBXW7 / FBW7 (N-Terminus). This antibody is tested and proven to work in the following applications:

FBXW7 Protein Vector (Human) (pPM-C-HA)
PV052071 500 ng
EUR 577.2

FBXW7 Protein Vector (Mouse) (pPM-C-HA)
PV178884 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPM-C-HA)
PV178888 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPM-C-HA)
PV178892 500 ng
EUR 723.6

FBXW7 Protein Vector (Human) (pPB-C-His)
PV052069 500 ng
EUR 577.2

FBXW7 Protein Vector (Human) (pPB-N-His)
PV052070 500 ng
EUR 577.2

FBXW7 Protein Vector (Human) (pPM-C-His)
PV052072 500 ng
EUR 577.2

FBXW7 Protein Vector (Mouse) (pPB-C-His)
PV178882 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPB-N-His)
PV178883 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPM-C-His)
PV178885 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPB-C-His)
PV178886 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPB-N-His)
PV178887 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPM-C-His)
PV178889 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPB-C-His)
PV178890 500 ng
EUR 723.6

FBXW7 Protein Vector (Mouse) (pPB-N-His)
PV178891 500 ng
EUR 723.6

FBXW7 Protein Vector (Mouse) (pPM-C-His)
PV178893 500 ng
EUR 723.6

FBXW7 3'UTR Luciferase Stable Cell Line